MAP PHARMACEUT (NASDAQ:MAPP)
9.20
0.03 (0.33%)
| MAP PHARMACEUT (NASDAQ:MAPP) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $9.23 | 52 Week High | $13.85 | ||
| Open | $9.26 | 52 Week Low | $1.57 | ||
| Day High | $9.26 | P/E | N/A | ||
| Day Low | $9.10 | EPS | $-0.98 | ||
| Volume | 134,624 | ||||
| More MAPP Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| GM | 4 | RMBS | 2 |
| SQNM | 2 | RSH | 2 |
| AZN | 2 | ARP | 2 |
| CYTK | 2 | OCLS | 2 |
| SEED | 2 | DDR | 2 |
| SNDK | 2 | EXAR | 2 |
Entities who have mentioned MAPP
- Deutsche Bank | View Related Stories »
- Banc of America | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Lazard | View Related Stories »
- Dividend | View Related Stories »
- S3 | View Related Stories »
- JPMorgan | View Related Stories »
- Barclays | View Related Stories »
- Collins Stewart | View Related Stories »
- Barack Obama | View Related Stories »
View All Major News StreetInsider.com Major News for MAPP
- MAP Pharmaceuticals (MAPP) Reports Smaller-Than-Expected Loss; Comments on Outlook
- MAP Pharmaceuticals (MAPP) Phase 3 Trial of LEVADEX Migraine Product Candidate Meets All Four Primary Endpoints
- MAP Pharma (MAPP) Reports Q4 Loss of $1.07
View All ReportsStreetInsider.com Reports on MAPP
- MAP Pharma. (MAPP) Secures $60M Equity Financing Facility with Azimuth Opportunity
- Jazz Pharmaceuticals (JAZZ) Running On Buy From Smart Investor
- MAP Pharmaceuticals (MAPP) Prices 3.5M Shares at $9.70
- MAP Pharmaceuticals (MAPP) Reports Smaller-Than-Expected Loss; Comments on Outlook
- Leerink Swann Upgrades MAP Pharmaceuticals (MAPP) to Outperform
View All Press ReleasesCompany Press Releases on MAPP
- MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
- MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
StreetInsider Reports on MAPP by Category
View All BlogsBlogs on MAPP
- Biotech Discounts Galore
- Closing Update for Thursday July 16
- Analyst upgrades, downgrades and initiations: CAL, NETL, MAPP, DDUP, LMT ...
- Buying ViroPharma Ahead of June 3rd FDA Decision
- Analyst upgrades, downgrades and initiations: PCZ, ALU, BIG, GOOG ...
View All FilingsSEC Filings on MAPP
- Form 4 MAP Pharmaceuticals, For: Nov 18 Filed by: HENWOOD GERALDINE
- Form 10-Q MAP Pharmaceuticals, For: Sep 30
- Form 8-K MAP Pharmaceuticals, For: Nov 05
- Form 4 GIANAKAKOS ANASTASIOS For: Nov 02
- Form 4 CHAI CHRISTOPHER Y For: Nov 02
Comments on MAPP
No comments are currently available.
